- 价格:
- 1700
- 规格:
- 400MG
- 包装:
- 28片
Sofosbuvir is a revolutionary new hepatitis C drug developed by Gilead in 2006. It is a major breakthrough in the history of drugs in recent years. It has remarkable curative effect and few side effects and is favored by the majority of patients.
However, its high price has also discouraged many patients. The price of genuine Sofosbuvir tablets in the United States is as high as US$1.00 per tablet, a box of tablets, and a course of treatment, which is about 10,000 yuan per person. For most people, For some ordinary families, this is nothing more than exorbitantly expensive medicines.
In March 2019, after repeated negotiations and contests with Gilead, India finally launched sofosbuvir on the market, and Gilead granted authorization to many Indian pharmaceutical companies to produce the patented star drug sofosbuvir developed by it.
Sofosbuvir has been confirmed by countless patients and is undoubtedly a highly effective new drug for hepatitis C. It has solved the problem of low cure rate and high recurrence rate of hepatitis C with interferon in the field of hepatitis C in medical history. However, the high pricing of Gilead, the original manufacturer of sofosbuvir, has undoubtedly put the hopes of many ordinary families on the cliff.
Due to patent restrictions and strict monitoring by the Food and Drug Administration, China is unable to produce sofosbuvir tablets. At the beginning, major domestic pharmaceutical companies also predicted that sofosbuvir would become a major hit in the history of drugs. Bomb, many important factories have imitated, produced and supplied sofosbuvir intermediates, APIs, etc. China is the world's largest API country and leads the world in exports of APIs every year. The emergence of sofosbuvir has undoubtedly become a This powerful motivation. However, due to the special management system, it will still take several years for sofosbuvir to be launched in China.
The combination of sofosbuvir + daclatasvir can effectively kill the hepatitis C virus. Current relevant experiments have proven that the cure rate of sofosbuvir + daclatasvir for hepatitis C is as high as over %.
Product formula specifications daclatasvir//bottle/fibre/box
For more information about sofosbuvir and daclatasvir products, please contact